VivoSim Labs, Inc. (LON:0R02)
0.2645
+0.0054 (2.08%)
Mar 20, 2025, 5:32 PM GMT
VivoSim Labs Revenue
VivoSim Labs had revenue of $26.00K USD in the quarter ending December 31, 2025, with 8.33% growth. This brings the company's revenue in the last twelve months to $142.00K, up 16.39% year-over-year. In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth.
Revenue (ttm)
$142.00K
Revenue Growth
+16.39%
P/S Ratio
34.78
Revenue / Employee
$10.92K
Employees
13
Market Cap
3.67M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Futura Medical | 7.93M |
| OptiBiotix Health | 1.15M |
| Physiomics | 834.16K |
| BSF Enterprise | 52.84K |
| ValiRx | 49.78K |
| CRISM Therapeutics | 25.00K |
VivoSim Labs News
- 10 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 10 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 11 months ago - Organovo reports $11.3M cash balance in FY24 - Seeking Alpha
- 11 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 11 months ago - Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
- 11 months ago - Organovo Provides Business Update - GlobeNewsWire
- 11 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire
- 11 months ago - Organovo announces reverse stock split; shares fall - Seeking Alpha